Blog
Enoblituzumab Biosimilar : A New Era in B7-H3-Targeted Cancer Immunotherapy
Enoblituzumab is a monoclonal antibody targeting B7-H3 (CD276), a member of the B7 family of immune checkpoint proteins. B7-H3 is overexpressed in various cancers and contributes to immu
…
28th Nov 2024